A Case of Transformation of Primary Cutaneous Follicle Center Lymphoma to Diffuse Large B-Cell Lymphoma Involving the Parotid Gland and Cervical Lymph Nodes.
Journal
The American journal of case reports
ISSN: 1941-5923
Titre abrégé: Am J Case Rep
Pays: United States
ID NLM: 101489566
Informations de publication
Date de publication:
29 Aug 2019
29 Aug 2019
Historique:
entrez:
30
8
2019
pubmed:
30
8
2019
medline:
6
2
2020
Statut:
epublish
Résumé
BACKGROUND Transformation of primary cutaneous follicle center lymphoma (PCFCL), a low-grade B-cell non-Hodgkin lymphoma (NHL), into a high-grade NHL is rare with uncertain prognosis and treatment. A case is reported of a 40-year-old man who presented with a scalp mass that was diagnosed histologically as PCFCL. Imaging of the head and neck identified diffuse large B-cell lymphoma (DLBCL) involving the parotid gland and cervical lymph nodes, which responded well to radiation therapy. CASE REPORT A 40-year-old African American man presented with a two-year history of a progressively enlarging scalp mass that measured 10.5×7.1×6.6 cm. Histology showed a low-grade lymphoma with a follicular pattern. Immunohistochemistry was positive for B-cell markers and Bcl-6, consistent with a diagnosis of PCFCL. Computed tomography (CT) identified a 4.9×3.7×3.4 cm mass in the left parotid gland with bilateral cervical lymphadenopathy that had been present for the previous two or three months. The diagnosis of DLBCL was made on histology from a needle biopsy. Treatment began with rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (R-EPOCH) chemotherapy, followed by radiation therapy to the scalp, both sides of the neck, and left parotid gland. At four-month follow-up, combined positron emission tomography (PET) and CT showed only diffuse low-level uptake in the scalp and parotid gland. CONCLUSIONS Transformation of low-grade PCFCL to high-grade DLBCL is rare, and the approach to treatment varies. This case showed a good response to chemotherapy and radiation therapy.
Identifiants
pubmed: 31462626
pii: 917389
doi: 10.12659/AJCR.917389
pmc: PMC6735615
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1273-1278Références
Ann Oncol. 2003 Jan;14(1):131-9
pubmed: 12488305
J Clin Oncol. 2008 Nov 10;26(32):5165-9
pubmed: 18838711
Blood. 2009 May 21;113(21):5064-73
pubmed: 19279331
Case Rep Med. 2010;2010:296523
pubmed: 20589072
Chin Clin Oncol. 2015 Mar;4(1):10
pubmed: 25841717
Blood. 2015 Aug 13;126(7):851-7
pubmed: 26105149
Oncotarget. 2016 Jul 5;7(27):41242-41250
pubmed: 27183909
Lancet. 2017 Jul 15;390(10091):298-310
pubmed: 28153383
Indian J Dermatol. 2017 Mar-Apr;62(2):146-157
pubmed: 28400634
Pathology. 2018 Jan;50(1):74-87
pubmed: 29167021
Postepy Dermatol Alergol. 2017 Dec;34(6):625-628
pubmed: 29422831